News - Patents

Filter

Current filters:

Patents

Popular Filters

1 to 25 of 425 results

US court preliminary order to prevent Actavis launch of generic Gralise

US court preliminary order to prevent Actavis launch of generic Gralise

18-07-2014

Judge Joel Pisano of the US District Court for the District of New Jersey has entered an order preliminarily…

ActavisActavis Elizabeth LLCAnticonvulsantsDepomedGenericsGraliseHealth Medical PharmaLaw CrimeLegalNeurologicalPatentsPfizerUSA

Actavis confirms patent challenge to Duchesnay’s Diclegis

Actavis confirms patent challenge to Duchesnay’s Diclegis

12-07-2014

Ireland-based generics major Actavis on Friday confirmed that it has filed an Abbreviated New Drug Application…

ActavisDiclegisDuchesnayGenericsPatentsRegulationUSAWomen's Health

Report: Why pharmaceutical prices drop once drugs are off-patent

Report: Why pharmaceutical prices drop once drugs are off-patent

07-07-2014

The USA-based Pacific Research Institute has released a new report, titled The Economics of Pharmaceutical…

GlobalPatentsPharmaceuticalPricing

Teva files citizen petition with FDA regarding Copaxone complexity

Teva files citizen petition with FDA regarding Copaxone complexity

03-07-2014

Teva Pharmaceutical Industries says it has filed a citizen petition regarding the approvability of purported…

CopaxoneLegalNeurologicalPatentsPharmaceuticalRegulationTeva Pharmaceutical IndustriesUSA

Biotech clusters with patent strategies are more attractive to big pharma

Biotech clusters with patent strategies are more attractive to big pharma

01-07-2014

Life sciences and biotech research clusters across the UK are benefiting from an improved funding climate…

BiotechnologyFinancialPatentsUK

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Shire gets positive ruling on Vyvanse patents from US district court

25-06-2014

Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from…

ActavisAmneal PharmaLegalMylanNeurologicalPatentsPharmaceuticalRoxaneSandozShireUSAVyvanse

US Court denies appeal in Baraclude patent case

US Court denies appeal in Baraclude patent case

13-06-2014

US pharma major Bristol-Myers Squibb yesterday announced that the US Court of Appeals for the Federal…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLegalPatentsTeva Pharmaceutical IndustriesUSA

Lupin no longer trying to market generics of Truvada and Viread

Lupin no longer trying to market generics of Truvada and Viread

08-06-2014

Indian drugmaker Lupin seems to have abandoned plans to bring to market generic versions of Gilead Sciences’…

Anti-viralsGenericsGilead SciencesLegalLupinPatentsTruvadaUSAViread

Actavis brings escitalopram to market after patent expiry

Actavis brings escitalopram to market after patent expiry

02-06-2014

Generics major Actavis (NYSE: ACT) has launched escitalopram tablets in the UK today, following the patent…

ActavisCNS DiseasesEscitalopramEscitalopram OxalateGenericsLexaproLundbeckPatentsUK

Pharma backs the new Unified Patent Court for majority of future filings

Pharma backs the new Unified Patent Court for majority of future filings

02-06-2014

There is growing support for Europe’s hotly debated Unified Patent Court, with almost three-quarters…

EuropeIntellectual property lawLegalNicola DaggPatentsPharmaceuticalUnitary Patent Court

Actavis settles Nuvigil patent litigation with Cephalon

Actavis settles Nuvigil patent litigation with Cephalon

01-06-2014

Ireland-headquartered generics major Actavis says it has entered into an agreement with Cephalon to settle…

ActavisCephalonGenericsLegalNeurologicalNuvigilPatentsTeva Pharmaceutical IndustriesUSA

BioTime's subsidiary Asterias settles patent interference proceedings with ViaCyte

29-05-2014

US biotech firm BioTime says its subsidiary Asterias Biotherapeutics has entered into a settlement agreement…

Asterias BiotherapeuticsBiotechnologyBioTimeLegalPatentsUSAViaCyte

Joint position to grow Australia's biopharmaceutical industry

Joint position to grow Australia's biopharmaceutical industry

29-05-2014

Trade groups AusBiotech and Medicines Australia this morning published a joint statement sent to the…

AustraliaBiotechnologyFinancialMarkets & MarketingPatentsPharmaceuticalResearch

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

28-05-2014

Generics major Actavis yesterday confirmed that it has filed an Abbreviated New Drug Application with…

ActavisAstraZenecaDiabetesGenericsOnglyzaPatentsUSA

Lilly loses out in UK Alimta vitamin dosage regimen patent law suit

16-05-2014

US pharma major Eli Lilly says that the English High Court has determined that the vitamin dosage regimen…

ActavisAlimtaEli LillyGenericsLegalOncologyPatentsUK

Government tables amendment to attract drug research back to the UK

15-05-2014

The UK government is moving ahead with plans to amend legislation to attract drug research back to the…

PatentsPharmaceuticalPoliticsResearchUK

US Court rejects Teva’s Copaxone appeal

15-05-2014

A US district court has dismissed a case by Israeli drugmaker Teva Pharmaceutical Industries intended…

CopaxoneGenericsLegalMylanNeurologicalPatentsTeva Pharmaceutical IndustriesUSA

Novartis patent settlement on Gleevec with Sun Pharma subsidiary

15-05-2014

The US unit of Swiss drug major Novartis has settled its litigation with the US subsidiary of India’s…

GenericsGleevecNovartisOncologyPatentsSun Pharmaceutical IndustriesUSA

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

13-05-2014

The challenges posed by expiring patents, the global economic slowdown, and price premium pressures are…

Mergers & AcquisitionsPatentsPharmaceutical

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

India’s bio-pharma market forecast to reach $7 billion by FY2015

08-05-2014

Growing at an average rate of about 20%, India’s biotech industry comprising bio-pharmaceuticals, bio-services,…

BiotechnologyIndiaMarkets & MarketingPatentsResearch

1 to 25 of 425 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top